Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials

Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer

(2012) Alessandro Passardi et al.   Journal of Translational Medicine

Severe interstitial pneumonitis associated with the administration of taxanes

(2010) Shigeyuki Nagata et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104)

(2009) K. Takeda et al.   ANNALS OF ONCOLOGY

Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG)

(2009) Antoaneta Tomova et al.   BREAST CANCER RESEARCH AND TREATMENT

Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma

(2009) Flávio Henrique Ferreira Galvão et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma

(2009) Joaquín Casal Rubio et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Adjuvant gemcitabine plus docetaxel for completely resected stages I–IV high grade uterine leiomyosarcoma: Results of a prospective study

(2009) Martee L. Hensley et al.   GYNECOLOGIC ONCOLOGY

Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer

(2009) Stephen Chan et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer

(2009) Silvia Novello et al.   LUNG CANCER

Weekly Docetaxel with or without Gemcitabine as Second-Line Chemotherapy in Paclitaxel-Pretreated Patients with Metastatic Breast Cancer: A Randomized Phase II Study Conducted by the Hellenic Co-Operative Oncology Group

(2009) Christos A. Papadimitriou et al.   ONCOLOGY

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

(2008) G. Fountzilas et al.   BREAST CANCER RESEARCH AND TREATMENT

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial

(2008) Martee L. Hensley et al.   GYNECOLOGIC ONCOLOGY

Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy

(2008) Chao Hui Huang et al.   Journal of Thoracic Oncology

Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer

(2008) Se Hoon Park et al.   LUNG CANCER

Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: A multicenter phase II study

(2008) I. Boukovinas et al.   LUNG CANCER

Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells

(2008) Gerta Rücker et al.   STATISTICS IN MEDICINE

Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: A randomized, multicenter phase III trial

(2007) Vassilis Georgoulias et al.   LUNG CANCER